Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Growth and Prolactin Effects of Risperidone in Children
NCT01050582Phase 4Completed
- Sponsor
- Johnson & Johnson
- Start
- Oct 2009
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 4 trial of risperidone in schizophrenia, bipolar disorder (BD), Autism Spectrum Disorder (ASD), conduct disorder (CD), Disruptive behavior disorders (DBD), sponsored by Johnson & Johnson. Started Oct 2009; status: completed.
02
Drugs
risperidone
03
Conditions
schizophreniabipolar disorder (BD)Autism Spectrum Disorder (ASD)conduct disorder (CD)Disruptive behavior disorders (DBD)
Beyond the preview
Go deeper on NCT01050582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01050582.